CLOVER CORPORATION LIMITED (CLV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CLV - CLOVER CORPORATION LIMITED

FNArena Sector : Health & Nutrition
Year End: July
GICS Industry Group : Health Care Equipment & Services
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.46

15 Sep
2021

0.000

OPEN

$1.45

0.000

HIGH

$1.47

203,662

LOW

$1.40

TARGET
$2.185 49.7% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
EBO . MCP . API . BKL . EXL . SIG .
FNARENA'S MARKET CONSENSUS FORECASTS
CLV: 1
Title FY19
Actual		 FY20
Actual		 FY21
Forecast		 FY22
Forecast
EPS (cps) xxx 7.5 4.3 xxx
DPS (cps) xxx 2.5 1.6 xxx
EPS Growth xxx 22.7% - 42.7% xxx
DPS Growth xxx 5.3% - 36.0% xxx
PE Ratio xxx N/A 32.6 xxx
Dividend Yield xxx N/A 1.1% xxx
Div Pay Ratio(%) xxx 33.3% 37.2% xxx

Dividend yield today if purchased 3 years ago: 1.58%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.79

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 07/04 - 0.5c (100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201520162017201820192020
EPS Basic xxxxxxxxxxxxxxx7.5
DPS All xxxxxxxxxxxxxxx2.5
Sales/Revenue xxxxxxxxxxxxxxx88.3 M
Book Value Per Share xxxxxxxxxxxxxxx34.6
Net Operating Cash Flow xxxxxxxxxxxxxxx6.7 M
Net Profit Margin xxxxxxxxxxxxxxx14.14 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201520162017201820192020
Return on Assets xxxxxxxxxxxxxxx15.98 %
Return on Equity xxxxxxxxxxxxxxx24.32 %
Return on Total Capital xxxxxxxxxxxxxxx28.08 %
Capex xxxxxxxxxxxxxxx0.6 M
Capex % of Sales xxxxxxxxxxxxxxx0.63 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx3.2 M

Return on Assets

Return on Equity

Return on Total Capital

Capex

Capex % of Sales

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

UBS

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

17/03/2021

1

Buy

$2.37

62.33%

Clover Corp's first-half result was largely in line with Ord Minnett's expectations.

The infant formula market experienced continued volatility, leading to a -21.7% decline in total revenue over last year with the covid impacted Daigou channel a key victim.

Even so, the company managed to control costs throughout the half and delivered operating income of $4.1m, slightly ahead of the broker's expected $4m.

Ord Minnett considers Clover Corp well-placed with its global network of infant formula customers that enables the company to meet demand wherever it may arise first. 

Buy rating with the target falling to $2.37 from $2.47.

FORECAST
Ord Minnett forecasts a full year FY21 dividend of 1.50 cents and EPS of 4.70 cents.
Ord Minnett forecasts a full year FY22 dividend of 2.50 cents and EPS of 6.70 cents.
Access Stockbroker Research History >

CLV STOCK CHART

FNArena News on CLV

1
FNArena Corporate Results Monitor – 29-03-2021

Mar 29 2021 - Australia
2
Weekly Ratings, Targets, Forecast Changes – 19-03-21

Mar 22 2021 - Weekly Reports
3
Is Beijing Creating Buying Opportunities For Stocks?

Dec 16 2020 - FYI
4
FNArena Corporate Results Monitor – 23-09-2020

Sep 23 2020 - Australia
5
Next Week At A Glance – 14-18 Sep 2020

Sep 11 2020 - Weekly Reports

Latest Health & Nutrition News

1
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
2
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
3
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
4
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI
5
Next Week At A Glance – 14-18 Sep 2020

Sep 11 2020 - Weekly Reports
6
Sigma Farewells API, Heralds New Contract

Dec 17 2019 - Australia
7
Blackmores: Hopes Pinned On Restructuring

Nov 01 2019 - Australia
8
Blackmores Peps Up Its Strategy For China

Apr 17 2019 - Australia
9
API/Sigma Merger Plan Rears, Again

Dec 17 2018 - Australia
10
Uncertainty Hinders Sigma Pharmaceuticals

Sep 11 2018 - Small Caps